These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23385728)

  • 21. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma.
    Bazzi WM; Tin AL; Sjoberg DD; Bernstein M; Russo P
    Can J Urol; 2016 Feb; 23(1):8151-4. PubMed ID: 26892055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
    Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
    BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
    Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
    Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.
    Stotz M; Gerger A; Eisner F; Szkandera J; Loibner H; Ress AL; Kornprat P; AlZoughbi W; Seggewies FS; Lackner C; Stojakovic T; Samonigg H; Hoefler G; Pichler M
    Br J Cancer; 2013 Jul; 109(2):416-21. PubMed ID: 23799847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma.
    Bezan A; Mrsic E; Krieger D; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
    J Urol; 2015 Jul; 194(1):30-5. PubMed ID: 25623738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
    Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
    J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.
    Pedersen MM; Donskov F; Pedersen L; Zhang ZF; Nørgaard M
    Acta Oncol; 2020 Jan; 59(1):13-19. PubMed ID: 31448981
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
    Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
    Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.
    Vartolomei MD; Mathieu R; Margulis V; Karam JA; Rouprêt M; Lucca I; Mbeutcha A; Seitz C; Karakiewicz PI; Fajkovic H; Wood CG; Weizer AZ; Raman JD; Rioux-Leclercq N; Haitel A; Bensalah K; Rink M; Briganti A; Xylinas E; Shariat SF
    World J Urol; 2017 Jan; 35(1):121-130. PubMed ID: 27209168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
    Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
    PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.
    Vartolomei MD; Kimura S; Ferro M; Vartolomei L; Foerster B; Abufaraj M; Shariat SF
    World J Urol; 2018 Jul; 36(7):1019-1029. PubMed ID: 29468284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
    Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
    Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.